MarketWatchCenter·
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The Federal Trade Commission and seven states say Shkreli should be held in contempt
Read at MarketWatch →
Markets · 1 sources covering this
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The Federal Trade Commission and seven states say Shkreli should be held in contempt
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/e92a3b48475c0db28ea2410b732336c72e796b73" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks"></iframe>
